Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey

M Bradbury; M F Savard; C Stober; L Clemons; M Clemons; J Hilton; G Pond; L Vandermeer; S F McGee

doi:10.1007/s10549-024-07302-0

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey

Breast Cancer Res Treat. 2024 Apr 25. doi: 10.1007/s10549-024-07302-0. Online ahead of print.

Authors

M Bradbury¹, M F Savard^{2

3}, C Stober³, L Clemons³, M Clemons^{2

3}, J Hilton^{2

3}, G Pond⁴, L Vandermeer³, S F McGee^{5

6}

Affiliations

¹ Department of Medicine, Division of Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
² Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
³ Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
⁴ Department of Oncology, McMaster University, Hamilton, ON, Canada.
⁵ Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. shmcgee@toh.ca.
⁶ Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada. shmcgee@toh.ca.

PMID: 38664288
DOI: 10.1007/s10549-024-07302-0

Abstract

Purpose: Despite previous studies proposing shorter durations of anti-HER2 therapy for selected patients with HER2-positive early breast cancer (EBC), 12-months remains standard of care. A survey was performed to assess patient perspectives and willingness to participate in studies evaluating shorter durations of anti-HER2 therapy.

Methods: Patients with HER2-positive EBC completing or having previously completed anti-HER2 therapy, were recruited by healthcare professionals at The Ottawa Hospital Cancer Centre to participate in an anonymous online survey. The primary objective was to learn about patients' perspectives on shorter durations (less than 12-months) of anti-HER2 therapy. Secondary objectives were to explore patients' interest in clinical trials of shorter durations of anti-HER2 therapy and the degree of increased breast cancer risk they would accept with a shorter treatment duration.

Results: Responses were received from 94 eligible patients. Most patients received Trastuzumab alone (78%, 73/94), while 13% (12/94) received trastuzumab and pertuzumab. Side effects were experienced by 52% (46/89), the most common being; fatigue (61%, 28/46), myalgia (37%, 17/46), and diarrhea (24%, 11/46). Most patients (88%, 78/89) did not find treatment bothersome. Regarding perspectives on shorter durations of anti-HER2 therapy, most (79%, 74/94) respondents stated they would agree to less treatment if it were possible to receive fewer treatments with the same cancer benefits. 56% of patients were interested in clinical trials, however, about half stated they would not be accepting of any increase in breast cancer recurrence risk.

Conclusion: Trials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients' perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment.

Keywords: HER2-positive breast cancer; Patient perspectives; Shorter duration; Survey; anti-HER2 therapy.